Table 2.

NMR Data for Veraguamides B (2) and C (3) in CDCl₃

			2		3
unit	C/H no.	δ Ca	δH (J in Hz)b	δ Ca	δH (J in Hz)b
Br-Hmoyac/Hmoyad	1	170.8, C		170.8, C
	2	42.3, CH	3.13, br q (7.4)	42.4, CH	3.10, br q (7.2)
	3	76.4, CH	4.85, d (8.7)	76.4, CH	4.86, dt (10.4, 2.5)
	4a	27.5, CH2	2.07, m	27.4, CH2	2.07, m
	4b		1.60, m		1.62, m
	5a	24.93, CH2	1.61, m	25.2, CH2	1.62, m
	5b		1.42, m		1.44, m
	6	19.2, CH2	2.21, m	18.0, CH2	2.19, m
	7	38.4, C		83.6, C
	8	79.4, C		68.8, CH	1.93 t (2.5)
	9	14.6, CH3	1.25, d (7.4)	14.5, CH3	1.25, d (7.2)
N-Me-Val-1	1	170.7, C		170.7, C
	2	65.0, CH	3.94, d (10.4)	65.0, CH	3.93, d (11.0)
	3	28.26, CH	2.29, m	28.3, CH	2.28, m
	4	19.57, CH3	0.98, d (6.5)	19.58, CH3	0.98, d (6.8)
	5	19.55, CH3	0.92, d (6.5)	19.56, CH3	0.91, d (6.8)
	N-Me	28.7, CH3	3.00, s	28.7, CH3	3.00, s
Pro	1	172.1, C		172.2, C
	2	57.2, CH	4.95 dd (8.6, 4.8)	57.3, CH	4.94 dd (8.4, 5.0)
	3a	29.4, CH2	2.28, m	29.5, CH2	2.28, m
	3b		1.79, m		1.79, m
	4a	24.99, CH2	2.04, m	24.89, CH2	2.03, m
	4b		1.98, m		1.99, m
	5a	47.3, CH2	3.80, dt (−16.4, 6.9)	47.3, CH2	3.84, dt (−16.8, 7.1)
	5b		3.60, dt (−16.4, 6.9)		3.60, dt (−16.8, 7.1)
Hivac/Hmpad	1	165.8, C		165.9, C
	2	77.2, CH	4.85, d (8.7)	76.0, CH	4.89, d (9.4)
	3	29.6, CH	2.17, m	35.7, CH	1.98, m
	4	18.1, CH3	1.02, t (6.6)	24.81, CH2	1.54, m
					1.13, m
	5	18.5, CH3	0.93, d (6.6)	10.5, CH3	0.86, t (7.3)
	6			13.8, CH3	1.01, d (6.7)
N-Me-Val-2	1	169.6, C		169.6, C
	2	66.1, CH	4.15, d (10.2)	66.0, CH	4.13, d (10.0)
	3	28.34, CH	2.28, m	28.5, CH	2.28, m
	4	20.3, CH3	0.99, d (6.8)	20.4, CH3	0.99, d (6.4)
	5	20.1, CH3	1.11, d (6.8)	20.2, CH3	1.10, d (6.4)
	N-Me	30.0, CH3	2.94, s	30.0, CH3	2.93, s
Val	1	173.5, C		173.4, C
	2	52.8, CH	4.71, dd (8.6, 6.4)	52.8, CH	4.70, dd (8.6, 6.2)
	3	32.2, CH	1.98, m	32.1, CH	1.96, m
	4	20.3, CH3	0.94, d (6.4)	20.3, CH3	0.94, d (6.7)
	5	17.5, CH3	0.88, d (6.4)	17.6, CH3	0.87, d (6.7)
	NH		6.26, d (8.6)		6.26, d (8.6)

^a100 MHz

^b600 MHz

^cRefers to Compound 2

^dRefers to Compound 3